News Pharma Giants File Patent Infringement Suit Against India-Based Drugmaker Over IBS Medication 3 minute read December 17, 2024 ...

Medically reviewed by Kumkum S. Patel, MDMedically reviewed by Kumkum S. Patel, MD Stimulant laxatives are used to help with bowel movements, especially when there is a problem with moving the bowels ...

To understand the experience of patients with IBS with constipation (IBS-C) and and IBS with diarrhea (IBS-D), Salix, which sells Trulance and Xifaxan for use in the indications, asked a set of ...

Case Name: Bausch Health Ireland Ltd. v. Mylan Labs. Ltd., No. 21-10403 (SRC) (JSA), 2022 WL 683084 (D.N.J. Mar. 8, 2022) (Chesler, J.) Drug Product and Patent (s)-in-Suit: Trulance® (plecanatide ...

LAS VEGAS — In this video exclusive, Eric Shah, MD, MBA, of Dartmouth-Hitchcock Health in Lebanon, New Hampshire, discussed the use of Trulance in patients with chronic idiopathic constipation ...

Use of TRULANCE should be avoided in patients 6 years to less than 18 years of age. The safety and efficacy of TRULANCE have not been established in pediatric patients less than 18 years of age.

TRULANCE ® is a once-daily tablet approved by Health Canada for adults with IBS-C. With the exception of a single amino acid substitution for greater binding affinity, TRULANCE ® is structurally ...

First-year Trulance sales indicate Trulance has the potential to reach blockbuster status. New to market blocks are skewing trajectory trends in the market.

** SGYP is the top pct gainer among U.S. stocks before the opening bell ** Deal for $200 mln in cash and includes all rights to SGYP's lead drug Trulance, used to treat constipation ...

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TRULANCE and is publishing this notice of that determination as required by law. FDA has made the ...